These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26430791)

  • 1. Managing Risk in Hodgkin Lymphoma.
    Armitage JO; Chen RW; Moskowitz CH; Sweetenham J
    Clin Adv Hematol Oncol; 2015 Feb; 13(2 Suppl 1):1-19. PubMed ID: 26430791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group].
    Móciková H; Marková J; Gahérová Ľ; Král Z; Sýkorová A; Belada D; Procházka V; Martinková L; Papajík T; Kozák T
    Klin Onkol; 2016; 29(5):342-346. PubMed ID: 27739312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
    Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
    Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse).
    Ansell SM
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):75-86. PubMed ID: 24287069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory Hodgkin lymphoma.
    von Tresckow B; Engert A
    Curr Opin Oncol; 2013 Sep; 25(5):463-9. PubMed ID: 23942291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment.
    Rueda A; Olmos D; Viciana R; Alba E
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):389-92. PubMed ID: 16640815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of newly diagnosed advanced stage Hodgkin lymphoma.
    Uhm J; Kuruvilla J
    Blood Rev; 2012 Jul; 26(4):167-74. PubMed ID: 22542250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
    Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
    Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hodgkin Lymphoma: Diagnosis and Treatment.
    Ansell SM
    Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of advanced stage Hodgkin lymphoma.
    Advani R; Ai WZ; Horning SJ
    J Natl Compr Canc Netw; 2006 Mar; 4(3):241-7. PubMed ID: 16507271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
    Mociková H
    Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT?
    Hertzberg M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):123-47. PubMed ID: 24287072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Eur J Haematol; 2014 Jul; 93(1):1-8. PubMed ID: 24750367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.